Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.


In a year marked by economic uncertainty, regulatory shifts, and evolving therapeutic priorities, dealmaking in the pharmaceutical industry remains a critical lever for growth. IQVIA Pharma Deals Half-Year Review of 2025 offers a data-driven lens into where capital is flowing in global pharma, which assets are commanding premium valuations, and how top players are reshaping their pipelines.
Whether you're evaluating licensing opportunities, scouting M&A targets, or refining your portfolio, this report equips you with the insights to stay competitive and future-ready.
Download the report to benchmark your strategy, uncover high-value opportunities, and make smarter investment decisions for the second half of 2025.
Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.